CAMOQUIN HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Camoquin Hydrochloride patents expire, and what generic alternatives are available?
Camoquin Hydrochloride is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in CAMOQUIN HYDROCHLORIDE is amodiaquine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the amodiaquine hydrochloride profile page.
Summary for CAMOQUIN HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 5 |
Patent Applications: | 76 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CAMOQUIN HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CAMOQUIN HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
London School of Hygiene and Tropical Medicine | Phase 2 |
Pfizer | Phase 1 |
Pfizer | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for CAMOQUIN HYDROCHLORIDE
US Patents and Regulatory Information for CAMOQUIN HYDROCHLORIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Parke Davis | CAMOQUIN HYDROCHLORIDE | amodiaquine hydrochloride | TABLET;ORAL | 006441-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |